| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787805 | Journal of Thoracic Oncology | 2018 | 11 Pages |
Abstract
Nivolumab alleviates symptom burden and improves health status versus docetaxel as second-line squamous NSCLC treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Martin MD, PhD, Fiona MBiochem, John R. PhD, Michael PhD, Laura MPH, Homa PhD, Lucinda DPM, MPH, Richard J. MD,